We talked to Regeneron CEO George Yancopulos about his passion for science, his definition of success and the importance of patients.
Chimerix CEO Kenneth Moch discusses the business of biotech.
Listen to Memorial Sloan Kettering's Jose Baselga discuss his views on what the new phase I clinical trial in oncology should look like. His Bench to Bedside Keynote took place at the 2013 Cancer Advance at Harvard Medical School conference.
Listen to Infinity Pharmaceuticals' Julian Adams discuss the story of the Velcade. From his Bench to Bedside Keynote at the 2013 Cancer Advance at Harvard Medical School.
Listen to Nils Lonberg from BMS discuss how the pioneering immunotherapy drug Yervoy was developed. A Bench to Bedside Keynote from the 2013 Cancer Advance at Harvard Medical School.
Rafael Amado from GSK talks about the development of MEK inhibitors for melanoma during his Bench to Bedside Keynote at the 2013 Cancer Advance at Harvard Medical School.
George Yancopoulos, CEO of Regeneron, on why he likes to come to the BBC meetings.
Chimerix CEO Keneth Moch discusses the BBC meetings.